论文部分内容阅读
[目的]探讨原发性乳腺恶性淋巴瘤(PBL)的临床病理特点、诊治方法。[方法]回顾性分析28例原发性乳腺恶性淋巴瘤临床资料,中位年龄46岁(30～70岁)。按照AnnArbor分期标准,ⅠEA期14例,ⅡEA期8例,ⅢEA期3例,ⅢEB期1例,ⅣEA期2例;其中B细胞来源25例,外周T细胞来源3例。治疗情况:单纯手术组2例,单纯化疗组2例,综合治疗组24例;化疗一般采用CHOP方案,4～8个周期。[结果]随访时间6～139个月,中位随访时间62.5个月,全组患者中位生存时间为66个月(95%CI:50～84),5年生存率为45.6%。[结论]PBL病理以B细胞来源最常见。目前多选择化疗及放疗为基础结合手术的综合治疗,但仍有待多中心随机对照研究加以证实。
[Objective] To investigate the clinicopathological features, diagnosis and treatment of primary breast lymphoma (PBL). [Methods] The clinical data of 28 cases of primary malignant lymphoma of breast were analyzed retrospectively. The median age was 46 years old (30-70 years old). According to AnnArbor staging criteria, there were 14 cases of ⅠEA, 8 cases of ⅡEA, 3 cases of ⅢEA, 1 case of ⅢEB and 2 cases of ⅣEA. There were 25 cases of B cells and 3 cases of peripheral T cells. Treatment conditions: surgery alone group 2 cases, simple chemotherapy group 2 cases, comprehensive treatment group 24 cases; chemotherapy CHOP program generally used, 4 to 8 cycles. [Results] The follow-up time ranged from 6 to 139 months. The median follow-up time was 62.5 months. The median survival time was 66 months (95% CI: 50-84) and the 5-year survival rate was 45.6%. [Conclusion] The source of B cells is the most common in PBL pathology. The current multi-choice chemotherapy and radiotherapy-based combination of comprehensive treatment, but still to be multi-center randomized controlled studies to be confirmed.